Clinical trials located in

Tampere

Tampere city is located in Finland. Currently, 20 clinical trials are being conducted in this city.

Tampere, nestled between Näsijärvi and Pyhäjärvi lakes in Finland, is renowned for its rich industrial heritage. Founded in 1779, it’s the country’s third-largest city and a hub for culture and innovation. Tampere is home to the iconic Näsinneula Observation Tower, offering panoramic views, and the historic Finlayson factory area, reflecting its industrial past. The city also boasts the unique Spy Museum and the Moomin Museum, celebrating Tove Jansson’s beloved characters. Tampere’s vibrant culinary scene, with its famous mustamakkara (black sausage), showcases its cultural diversity.

  • CT-EU-00121743

    Study comparing Giredestrant and Fulvestrant with CDK4/6 Inhibitors for advanced breast cancer

    This study focuses on a type of advanced breast cancer known as Estrogen Receptor-Positive (ER+), HER2-Negative breast cancer. This kind of cancer is driven by hormones and does not have high levels of the HER2 protein. The study aims to evaluate the effectiveness and safety of a new drug called Giredestrant compared to an existing drug called Fulvestrant. Both drugs will be combined with one of three medicines that inhibit proteins in cancer cells called CDK4/6 inhibitors (Palbociclib, Ribociclib, or Abemaciclib).

    In this study, participants will be randomly assigned to one of two groups. One group will receive Giredestrant and the other will receive Fulvestrant. Both groups will also receive one of the CDK4/6 inhibitors chosen by their doctor. These combinations are being tested to see which works better to stop the cancer from growing or spreading.

    The drugs involved include Giredestrant (RO7197597, RG6171, GDC-9545), Fulvestrant, Abemaciclib, Palbociclib, Ribociclib, and LHRH Agonist (for pre/perimenopausal women and men).

    The goal is to find out if Giredestrant can provide better results and fewer side effects compared to Fulvestrant when both are combined with one of the CDK4/6 inhibitors. The study may involve regular tests and assessments to monitor the cancer’s progress and the patient’s response to the treatment.

    Participants will continue to receive the study drugs as long as they are benefiting from them and not experiencing unacceptable side effects. The study involves close monitoring to ensure the safety and well-being of all participants throughout the treatment period.

    • LHRH Agonist
    • Abemaciclib
    • Giredestrant
    • Palbociclib
    • Ribociclib
    • Fulvestrant
  • Testing a new drug for advanced prostate cancer

    This trial compares a new drug called AZD5305 with a placebo in men who have a specific kind of prostate cancer that has not responded to usual treatment methods. It’s a large trial, with around 1800 participants, and the main aim is to see whether the new treatment can help slow down the disease for longer than current treatments. Participants will be assigned to two different groups, and they will not know whether they’re receiving the real drug or the placebo. Their health will be monitored closely, with regular scans to check the progress of the cancer. The trial will also look at any side effects of the treatment and how it affects the patients’ ability to do their daily activities.

    • Enzalutamide/Xtandi
    • Darolutamide/Nubequa
    • Abiraterone Acetate/Zytiga
    • Saruparib
  • Testing new immunotherapy combinations for non-small-cell lung cancer

    This study is testing a new treatment for non-small cell lung cancer that has not yet been treated with drugs. In the study, researchers will look at the effects of combining different immunotherapy drugs and their safety and effectiveness in treating cancer. Participants will receive various combinations of the drugs pembrolizumab, dostarlimab, belrestotug and GSK6097608. The study will last several years and will monitor the effects of different drug combinations and any potential side effects. The study aims to find new ways to treat lung cancer with fewer negative side effects.

    • Belrestotug
    • Dostarlimab
    • GSK6097608- new potential medication for solid tumors
    • Pembrolizumab
  • Study on new immunotherapy combinations for untreated advanced lung cancer

    This is a study of patients whose non-small cell lung cancer is at an advanced stage (cannot be cured by surgery or has spread to other parts of the body) and has not been previously treated. The study will test new combinations of immunotherapy (drugs that support the immune system in the fight against cancer) and compare them with a single immunotherapy drug. Scientists want to find out how well these combinations work and how safe they are. The study will also look at how the body processes these drugs. The drugs used in this study are called Belrestoug, GSK4428859A and EOS884448, but these names all refer to the same drug. Scientists will measure the effectiveness of the drugs by looking at how many patients have their cancer shrink and how long it takes for the cancer to start growing again or before the patient dies. They will also record any side effects that may occur during the study and for 90 days after the last treatment dose.

    • Belrestotug
    • Dostarlimab
    • GSK6097608- new potential medication for solid tumors
    • Pembrolizumab
  • Study of new drug ARV-471 (PF-07850327) and fulvestrant in patients with advanced breast cancer

    The study looks at advanced breast cancer that has spread to other parts of the body (metastasizes). It is aimed at patients with ER+/HER2- breast cancer, which means that the cancer responds to estrogen (a hormone) and does not have excessive amounts of the HER2 protein. The study will compare two drugs: ARV-471 (PF-07850327, vepdegestrant) and fulvestrant.

    Fulvestrant is a drug already used to treat breast cancer, while ARV-471 is a new drug. The aim of this study is to determine whether ARV-471 is safe and effective compared to fulvestrant in patients with advanced breast cancer that cannot be cured by surgery or radiotherapy.

    The study is open to adults with breast cancer recurrence or metastases that cannot be fully cured by surgery or radiotherapy. Candidates should have a confirmed diagnosis of ER+/HER2- breast cancer and previous treatment with CDK4/6 inhibitors combined with hormonal therapy. Patients must not have active brain metastases or liver, kidney or bone marrow failure.

    Treatment continues until the cancer gets worse or the side effects become too severe. Clinic meetings take place approximately every 4 weeks.

    • Vepdegrestrant/ARV-471
    • Fulvestrant
  • Evaluating dostarlimab for treating stage III colon cancer

    This research is focused on the investigation of the effect of dostarlimab on patients with severe, untreated colon cancer (T4N0 or Stage III dMMR/MSI-H). The primary objective is to assess whether dostarlimab yields superior outcomes for the patients in comparison to standard treatments. Patient monitoring will be based on tumor response and the potential impact on their quality of life resulting from the drug or disease progression.

    • CAPEOX
    • Dostarlimab
    • FOLFOX
  • Evaluation of Bemarituzumab in patients with solid tumors overexpressing the FGFR2b receptor

    The study concerns patients with solid tumors that are characterized by excessive expression of the FGFR2b receptor (Fibroblast Growth Factor Receptor 2b). In particular, this includes cancers such as head and neck squamous cell carcinoma, triple negative breast cancer, intrahepatic cholangiocarcinoma, lung adenocarcinoma, epithelial ovarian cancer, endometrial adenocarcinoma and cervical cancer. The therapy that will be used in this study is bemarituzumab (also known as AMG 552), administered by intravenous infusion.

    The aim of the study is to assess the safety and tolerability of bemarituzumab and its preliminary anticancer effectiveness. Patients with the above cancers whose disease recurs or does not respond to standard therapies may be eligible to participate in the study.

    Patients must have confirmed recurrent or refractory cancer that is not suitable for surgical treatment. An additional condition is excessive expression of the FGFR2b receptor in their tumor. The experimental therapy includes two phases: in the first phase, determining the optimal dose, and in the second, expanding the therapy to a larger group of patients using a previously determined dose.

    • Bemarituzumab
  • Testing the effectiveness of a new drug compared with standard therapy in the treatment of asthma

    This medical research is a year-long study that tests a new asthma medication, called GSK3511294 (Depemokimab), against two other asthma medicines, Mepolizumab and Benralizumab. The trial is intended for teens and adults who have a severe form of asthma called ‘eosinophilic phenotype.’ The aim is to see if switching to GSK3511294 from Mepolizumab or Benralizumab keeps the severity and frequency of asthma attacks under control equally or better. Participants will keep taking their regular non-biological asthma medications throughout the trial. The study will look at the number of severe asthma attacks a patient experiences in a year, which is defined here as any worsening of asthma requiring steroids, a hospital visit, or an emergency room trip. They will also check for changes in their quality of life and their asthma control using questionnaires, and measure the capacity of their lungs with a breathing test.

    • GSK3511294 (Depemokimab)
    • Mepolizumab
    • Benralizumab
  • To study the efficacy and safety of Alpelisib and Fulvestrant in patients with advanced breast cancer after prior treatment

    The study is aimed at patients with advanced breast cancer, which is hormone-dependent (HR+) and HER2-negative, which means that cancer cells develop under the influence of hormones and at the same time do not have a large number of HER2 receptors. Patients must have a mutation in the PIK3CA gene and progressive cancer after previous therapy with CDK4/6 inhibitors and aromatase inhibitors.

    The study will use two drugs: Alpelisib, administered in the form of tablets, and Fulvestrant, administered as intramuscular injections. Both of these therapies will be compared with placebo in combination with fulvestrant. The aim of the study is to evaluate the effectiveness and safety of combined treatment with alpelisib and fulvestrant compared to placebo plus fulvestrant.

    • Alpelisib
    • Fulvestrant
  • Comparing the effectiveness of two treatments for severe nasal polyps and asthma

    This study is looking at two medications, called Dupilumab and Omalizumab, to see how well they work in people who have severe nose and sinus problems alongside asthma. The main goal is to see if Dupilumab is better at shrinking nasal polyps (small growths in the nose) and improving the sense of smell. Other goals include seeing if Dupilumab can improve symptoms, lung function, and overall health-related quality of life better than Omalizumab. The study also aims to understand how these drugs affect the severity of the disease and asthma control, and their safety. To assess all these, doctors will use various tests, like measuring the size of nasal polyps, testing the ability to smell, and how well one’s lungs are working. Participants in the study will be involved for 38 weeks.

    • Dupilumab
    • Omalizumab
  • Inhalation therapy study for Alpha-1 Antitrypsin deficiency

    This study focuses on Alpha-1 Antitrypsin Deficiency (AATD), a genetic condition that can lead to lung diseases such as emphysema. The study aims to evaluate the safety and effectiveness of an inhaled therapy using a drug called “Kamada-AAT for Inhalation” in adults who have moderate to severe airflow limitation due to AATD.

    The therapy being tested involves the daily inhalation of 80 mg of the Kamada-AAT drug using a nebulizer. This method is being compared to a placebo to assess its impact. By delivering the medication directly to the lungs, the study hopes to achieve better outcomes than traditional intravenous infusions.

    The primary purpose of this study is to determine if this inhaled treatment can improve lung function over time. Researchers will measure how well the lungs perform after 104 weeks of treatment. They will also look at changes in lung density and the overall health and quality of life of the participants.

    • Alpha 1-Antitrypsin
  • Testing tovorafenib in treating low-grade glioma

    This study is a comparative test between tovorafenib (DAY101) and the standard chemotherapy typically administered to children with low-grade glioma, a specific type of brain tumor. The experiment involves approximately 400 children who have not yet received treatment for their glioma. The participants will be divided into two groups. In the first group, children will be administered DAY101, taking it every 28 days until one of the following events occurs: they no longer benefit from the treatment, it becomes unsafe, they choose to leave the experiment, or the experiment concludes. In the second group, children will receive one of three common chemotherapy drugs selected by their doctor, and they will continue with the treatment until similar circumstances prompt a change, as outlined for the first group. If the tumor continues to grow while on DAY101 but the treatment remains beneficial, participants can continue taking it. Likewise, if the tumor continues to grow while on chemotherapy, participants can stop and transition to DAY101.

    • Tovorafenib/DAY101
  • Comparison of different treatments for follicular lymphoma

    This study involves comparing two treatments for a condition known as follicular or marginal zone lymphoma, both of which are types of cancer affecting lymph cells. The first treatment combines zanubrutinib with an antibody called Anti-CD20, while the second treatment involves lenalidomide and rituximab. These treatments are intended for patients who have not responded or have stopped responding to conventional treatment. One of the primary objectives of the study is to determine which treatment is more effective in preventing the cancer from progressing, referred to as progression-free survival. Additionally, the study aims to assess the impact of these treatments on the patients’ quality of life, evaluating various aspects through questionnaires related to physical and emotional well-being, symptoms, and the ability to perform normal activities.

    • Zanubrutinib
    • Obinutuzumab
    • Lenalidomide
    • Rituximab
  • Study on dazostinag & pembrolizumab for advanced solid tumors

    The purpose of this study is to test a new drug called dazostinag. A study is being conducted to see whether this drug is helpful in adults with advanced forms of solid cancer. Some people are given dazostinag alone, while others are given it with another medicine called pembrolizumab. Scientists’ focus here is on finding out whether these drugs cause any side effects, and finding out what the maximum dose is that people can take without serious side effects. The study consists of two parts, including a dose escalation phase and a dose escalation phase. In the first part, the dose of dazostinag will be gradually increased, given alone or in combination with pembrolizumab. In the second part, Dazostinag will be tested with pembrolizumab and other anticancer drugs. This section will focus on patients with specific cancers that are difficult to remove or have spread to other parts of the body.

    • Dazostinag
    • Platinum
    • Pembrolizumab
    • 5-Fluorouracil
  • Assessing olpasiran treatment for heart disease and elevated cholesterol

    Tests named ‘OCEAN(a)’ are being conducted, focusing on a medication called ‘olpasiran’. Put simply, the potential of this medication in preventing serious heart episodes in individuals with Atherosclerotic Cardiovascular Disease and an elevated level of a fat protein, Lipoprotein(a), is under examination. The effect of a harmless, dummy pill (placebo) is compared to that of the actual medication, olpasiran, in individuals with these conditions. The primary goal is to determine whether olpasiran can reduce the risk of death due to heart disease, occurrence of heart attacks, or the necessity for sudden surgery to clear blocked heart vessels.

    • Olpasiran
  • Radium-223 radiation vs. new hormone therapy in prostate cancer trial

    In this study, scientists are looking into two treatments for prostate cancer that has spread to the bone. One is a medicine called Radium-223 Dichloride or simply Xofigo which uses radiation to destroy cancer cells. The other is a new kind of treatment that stops hormones from working, as these hormones can sometimes help cancer grow. This new treatment is called Novel Anti-hormonal Therapy or NAH for short. The aim is to see which works better and to compare their safety profiles. Xofigo works by emitting a special type of radiation once it is injected into the body and absorbed by the bones. This radiation travels only a short distance, so it doesn’t harm healthy cells while killing cancerous ones. NAH, on the other hand, includes medications like abiraterone acetate (Zytiga) or enzalutamide (Xtandi) which are usually given to advanced prostate cancer patients. People taking part in this study will either receive Xofigo or NAH. Xofigo is given via an injection into a vein every 4 weeks for up to 6 months, while an oral form of NAH will be given daily until the disease progresses. Participants will be in this study for around 2 years, visiting the hospital or clinic every 2 weeks initially and then less often. There will be blood and urine tests and questionnaires about well-being and pain management.

    • Radium-223 dichloride/BAY88-8223
    • enzalutamide
    • prednisolone
    • abiraterone acetate
  • Impact of apalutamide on hormone-sensitive prostate cancer

    This is a study on prostate cancer, particularly patients suffering from a high-risk, hormone-sensitive form. The researchers want to check how adding a drug called apalutamide to the regular treatment can affect the cancer. The standard treatment includes radiotherapy and a drug that blocks the hormone responsible for cancer growth, known as LHRH. This study will check if adding apalutamide can delay the cancer from spreading or help patients live longer. The researchers will track disease progress using a special imaging test called PSMA-PET. They will also monitor changes in PSA, a protein made by the prostate that rises when cancer is present. Other important measures include how long it takes for the cancer to spread and the general rate of survival.

    • Apalutamide
  • Comparing darolutamide with standard therapy in hormone sensitive prostate cancer

    This study explores a combination therapy using darolutamide and androgen deprivation therapy (ADT) for men with high-risk biochemical recurrence of prostate cancer. ADT are treatments that block androgens production in the body. The trial aims to determine if this combination prolongs the time without cancer worsening or leading to death compared to ADT alone. Participants will be randomly assigned to receive either the combination treatment or a placebo with ADT for 24 months. The study will track cancer progression, overall health, and any side effects, offering potential advancements in prostate cancer treatment.

    • Darolutamide/BAY1841788
  • CT-EU-00036742

    Monitoring RSV vaccine safety in post-vaccination pregnancies

    This study tracks the safety of the RSVPreF3 vaccine in women who had it during previous pregnancies. It’s focused on women who are pregnant again after receiving the vaccine and will assess the health of both mothers and their babies. The study’s main aim is to understand any potential impacts of the vaccine on pregnancy outcomes and infant health. This research is important as it provides vital information on the safety of RSV vaccines in pregnant women, contributing to public health knowledge.

  • Studying effects of tozorakimab on Chronic Obstructive Pulmonary Disease (COPD)

    This clinical study evaluates the efficacy and safety of Tozorakimab in treating adults with Chronic Obstructive Pulmonary Disease (COPD) who have a history of frequent exacerbations. Participants, who must have experienced at least two moderate or one severe exacerbation in the past year, will receive tozorakimab through subcutaneous injections. The study aims to reduce the rate of COPD exacerbations over a one-year period. Participants will continue their usual inhaled lung therapies alongside the trial treatments.

    • Tozorakimab

See more clinical trials in other cities in Finland:

.